Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress
Lyell Immunopharma announced it will present updated Phase 1/2 safety and translational data for its lead candidate ronde-cel in large B-cell lymphoma at the EHA 2026 Congress in Stockholm. The two poster presentations will focus on low-grade cytokine release syndrome and neurotoxicity rates, as well as translational insights linking durable responses to cytotoxic T cells with memory potential.
Key figures
- Manufacturing capacity doses per year
- 1200
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.